| scholarly article | Q13442814 |
| P50 | author | Mamadou Dramé | Q104748926 |
| Frédéric Clement | Q51751601 | ||
| P2093 | author name string | Philippe Moris | |
| Emmanuel Hanon | |||
| Isabel Leroux-Roels | |||
| Marcelle Van Mechelen | |||
| Robbert van der Most | |||
| Geert G Leroux-Roels | |||
| P2860 | cites work | Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization. | Q51976793 |
| Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-gamma-secreting cells. | Q51985345 | ||
| Characterization of CD4+Memory T Cell Responses Directed against Common Respiratory Pathogens in Peripheral Blood and Lung | Q61863455 | ||
| Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis | Q77573851 | ||
| Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine | Q21144344 | ||
| Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages | Q24642180 | ||
| Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals | Q24648051 | ||
| Central memory and effector memory T cell subsets: function, generation, and maintenance | Q29615097 | ||
| Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine | Q30229190 | ||
| Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. | Q30341146 | ||
| Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. | Q30350403 | ||
| Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. | Q30363500 | ||
| Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. | Q30368814 | ||
| An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. | Q30370214 | ||
| MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults | Q30374764 | ||
| Current status and progress of prepandemic and pandemic influenza vaccine development. | Q30375975 | ||
| Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. | Q30376757 | ||
| Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. | Q30379899 | ||
| Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. | Q30381923 | ||
| The 2009 A (H1N1) influenza virus pandemic: A review | Q30390380 | ||
| Memory CD8 T-cell differentiation during viral infection | Q34152220 | ||
| Understanding the generation and function of memory T cell subsets | Q36123230 | ||
| Influenza and the challenge for immunology | Q36452600 | ||
| CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. | Q36494486 | ||
| Type I interferon as a stimulus for cross-priming | Q37027815 | ||
| Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels | Q37106916 | ||
| Standardization and optimization of multiparameter intracellular cytokine staining | Q37211056 | ||
| Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults | Q38392346 | ||
| Vaccine adjuvants alter TCR-based selection thresholds. | Q40096549 | ||
| Multiparameter flow cytometry monitoring of T cell responses | Q40802920 | ||
| Duration of humoral immunity to common viral and vaccine antigens | Q45872621 | ||
| Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. | Q46325181 | ||
| Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system | Q47756393 | ||
| P433 | issue | 3 | |
| P921 | main subject | vaccine | Q134808 |
| influenza vaccine | Q383260 | ||
| P304 | page(s) | 443-454 | |
| P577 | publication date | 2010-12-21 | |
| P1433 | published in | Journal of Clinical Immunology | Q6294961 |
| P1476 | title | H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses | |
| P478 | volume | 31 |
| Q30401247 | A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines |
| Q30379568 | A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03. |
| Q49157618 | A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults |
| Q37301506 | A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults |
| Q90636713 | AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells |
| Q30374665 | AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice. |
| Q30422038 | Adjuvant solution for pandemic influenza vaccine production |
| Q38442169 | Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials |
| Q57094841 | Adjuvanted influenza vaccines |
| Q30354814 | Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. |
| Q27007659 | Advances in aluminum hydroxide-based adjuvant research and its mechanism |
| Q30414122 | An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults |
| Q40782869 | An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice |
| Q30384943 | Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine. |
| Q30369654 | Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. |
| Q42248160 | CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy |
| Q92093930 | Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions |
| Q40151447 | Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison |
| Q35886612 | Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study |
| Q47573076 | Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial |
| Q35886910 | Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial |
| Q35918838 | Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years |
| Q96165356 | Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines |
| Q30364635 | Considerations for the rapid deployment of vaccines against H7N9 influenza. |
| Q30413695 | Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion |
| Q30353991 | Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. |
| Q36978351 | Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults |
| Q27000896 | H5N1 vaccines in humans |
| Q30361644 | Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization |
| Q64290749 | Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost |
| Q30362536 | History of narcolepsy at Stanford University. |
| Q47547355 | Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial |
| Q46313199 | Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women |
| Q42178340 | Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial |
| Q38105339 | Immunological assessment of influenza vaccines and immune correlates of protection |
| Q35874111 | Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. |
| Q49161794 | Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. |
| Q37951523 | Improving immunogenicity and effectiveness of influenza vaccine in older adults |
| Q38045918 | Influenza vaccines: T-cell responses deserve more attention |
| Q30367695 | Influenza vaccines: a moving interdisciplinary field. |
| Q30401398 | Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials |
| Q26314710 | Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children |
| Q30360190 | Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults. |
| Q30429185 | Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older |
| Q39262114 | Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice |
| Q30368937 | Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man. |
| Q30431078 | Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful |
| Q92853698 | Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial |
| Q90639926 | Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice |
| Q30371162 | Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization. |
| Q38813523 | Overview of Vaccine Adjuvants: Introduction, History, and Current Status |
| Q50105407 | Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. |
| Q49052310 | Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults |
| Q30371445 | Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. |
| Q61855992 | Precipitants of Narcolepsy: Vaccines and Infections |
| Q40199916 | Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination |
| Q30381595 | Refining the approach to vaccines against influenza A viruses with pandemic potential. |
| Q30362883 | Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. |
| Q92436768 | Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus |
| Q42279944 | Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. |
| Q35887417 | Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial |
| Q41162993 | Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting |
| Q91566045 | Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine |
| Q40565756 | Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study |
| Q30376727 | Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies |
| Q91577533 | Safety of AS03-adjuvanted influenza vaccines: A review of the evidence |
| Q37544974 | Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults. |
| Q42201392 | Seeking help: B cells adapting to flu variability |
| Q34067461 | Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. |
| Q38460087 | The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study |
| Q30417273 | The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants. |
| Q30426236 | Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine |
| Q35826767 | Vaccine Potentiation by Combination Adjuvants |
| Q91705195 | Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity |
| Q94545406 | Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives |
Search more.